Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
LOGOPHARM GmbH provides specialised services in proteomic target and biomarker R&D with a strong focus on membrane proteins and antibodies.
Founded in 2005 as a spinout of the University of Freiburg, Germany, the company combines most advanced technology and instrumentation with long-term experience in membrane protein analysis and molecular physiology to tackle even the most challenging targets, like ion channels, G-protein coupled receptors or other membrane receptors and transporters. Molecular characterisation of these targets delivers relevant information for drug development, such as post-translational modifications, subunit composition, interaction partners or changes in abundance.
The underlying proteomic approach is distinct from current high-throughput technologies that are based on recombinant systems and therefore suffer from high error rates, in that:
The leading performance of our technology has been well documented in numerous scientific publications.
Customers and partners may also benefit from our large internal database (more than 2,000 fully MS-analysed affinity purifications of membrane proteins and their interactors, covering a major portion of the mammalian proteome), our network of distinguished scientific collaborators, and reasonable policies concerning pricing and deal structures.
Logopharm GmbH
Schlossstr. 14
79232 March-Buchheim
Germany
Tel: +49 761 2035127
Fax: +49 761 2035191
info@logopharm.com
www.logopharm.com